Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome.
BACKGROUND Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain…
